Clinical Trial Update: Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of TPCA (docetaxel, cisplatin, irinotecan, and bevacizumab) in metastatic esophageal and gastric cancer has completed, with results posted on 2017…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• Platinol (cisplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Esophageal Cancer, Stomach Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-01-16